赛马鲁肽
医学
中止
利拉鲁肽
胰腺炎
艾塞那肽
胃排空
糖尿病
胰高血糖素样肽1受体
肠促胰岛素
急性胰腺炎
内科学
2型糖尿病
2型糖尿病
内分泌学
兴奋剂
受体
胃
作者
Zachary P. Morehouse,Jack D. Ledford
标识
DOI:10.1177/08971900241273188
摘要
Glucagon-like peptide 1 receptor agonists (GLP-1RA) are guideline recommended agents for the treatment of type 2 diabetes mellitus (T2DM) and select agents (liraglutide and semaglutide) are FDA approved as anti-obesity pharmacotherapy options. These drugs act on the incretin hormone system within the body to revive insulin excretion, delay gastric emptying, and inhibit the production of glucagon from pancreatic alpha cells. Acute pancreatitis is a serious condition that may have a fatal outcome. It has been shown, and is now part of the prescribing information label, that GLP-1RA agents can cause changes in the pancreas that may ultimately lead to pancreatitis. We describe the case of a 53-year-old female patient with uncontrolled type II diabetes mellitus, who experienced multiple episodes of pancreatitis, from what we suspect was due to repeated exposure to the GLP-1 RA agent, semaglutide. After discontinuation of semaglutide, our patient experienced another episode of pancreatitis roughly 15-week later; which we believe may be due to the patient experiencing the effects of a smoldering pancreas brought on by repeated injury and prolonged circulation of semaglutide post-discontinuation.
科研通智能强力驱动
Strongly Powered by AbleSci AI